Pharma BD Deal Intelligence
Pfizer Inc. / CStone Pharmaceuticals
2020 · Licensing/Option · $780M · Complete
Announcement Sentiment
92
Strongly positive
Outcome Score
51
Mixed — partial payoff, real shortfalls.
Pfizer licensed China commercialization rights to CStone's sugemalimab (PD-L1 antibody), paying $200M upfront including an $80M equity investment.
Key facts
- Announced Jul 08, 2020
- Closed Oct 11, 2020
- Deal value $780M
- Deal type Licensing/Option
- Therapeutic area Oncology
- Indications NSCLC, Gastric cancer, Multiple cancers
- Key assets sugemalimab
- Mechanism Anti-PD-L1 monoclonal antibody
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals